BB Biotech AG / Director's Dealings announcement according to §15a WpHG (the German Securities Trading Act) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Details of the person subject to the disclosure requirement | |
Name: | Strein, Klaus |
Professional role: | Person with executive functions: Member of administrative or supervisory body |
Designation of the financial instrument | |
ISIN: | CH0038389992 |
Designation: | Registered share BB Biotech AG |
Details of the transaction | |
Type of transaction: | Buy |
Date: | 04.02.2016 |
Place (stock exchange): | Swiss Stock Exchange |
Price: | 229.463 |
Currency: | CHF |
Quantity: | 2600 |
Business volume: | 596603.80 |
Details of the company with the publishing obligation: | |
Issuer: | |
BB Biotech AG | |
Schwertstrasse 6 | |
CH-8200 Schaffhausen | |
Switzerland |
ISIN: | CH0038389992 |
WKN: | 888509 |
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: BB Biotech AG via Globenewswire
--- End of Message ---
BB Biotech AG
Schwertstrasse 6 Schaffhausen Switzerland
WKN: 888509;ISIN: CH0038389992;Index:HDAX,MIDCAP,TecDAX,TECH All Share,Prime All Share;
Listed: Regulierter Markt in Frankfurter Wertpapierbörse;